Viveka Kumar

First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial

AIMSnThe MeRes-1 trial sought to study the safety and effectiveness of a novel sirolimus-eluting bioresorbable vascular scaffold (MeRes100 BRS) in treating de novo native coronary artery lesions by clinical evaluation and using multiple imaging modalities.nnnMETHODS AND RESULTSnThe MeRes-1 first-in-human trial was a single-arm, prospective, multicentre study, which enrolled 108 patients with de novo coronary artery lesions (116 scaffolds were deployed to treat 116 lesions in 108 patients). At six months, quantitative coronary angiography revealed in-scaffold late lumen loss of 0.15±0.23 mm with 0% binary restenosis. Optical coherence tomography demonstrated minimum scaffold area (6.86±1.73 mm2) and percentage neointimal strut coverage (99.30%). Quantitative intravascular ultrasound analysis confirmed a 0.14±0.16 mm2 neointimal hyperplasia area. At one year, major adverse cardiac events, a composite of cardiac death, any myocardial infarction and ischaemia-driven target lesion revascularisation, occurred in only one patient (0.93%) and there was no scaffold thrombosis reported. At one year, computed tomography angiography demonstrated that all scaffolds were patent and in-scaffold mean percentage area stenosis was 11.33±26.57%.nnnCONCLUSIONSnThe MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS. The favourable clinical outcomes and effective vascular responses have provided the basis for further studies in a larger patient population. The MeRes-1 trial is registered at the Clinical Trials Registry-India.

One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: The e-BioMatrix multicenter post marketing surveillance registry in India

OBJECTIVEnThe e-BioMatrix is a post marketing multicenter registry with an objective to evaluate the 2 year clinical safety and efficacy outcomes in patients treated with BioMatrix™xa0-xa0Biolimus A9™ (BA9™) drug eluting stents (DES).nnnBACKGROUNDnDrug-eluting stents still have late-stage disadvantages that might be attributable to the permanent polymer. BioMatrix a new generation DES containing anti-proliferative drug Biolimus A9™ incorporating a biodegradable abluminal coating that leaves a polymer-free stent after drug release enhancing strut coverage while preventing neointimal hyperplasia.nnnMETHODSnThis interim analysis consists of a total of 1189 patients with 1418 lesions treated with BioMatrix stent who entered this multicenter registry in India. We analyzed the incidence of major adverse cardiac events (MACE) and stent thrombosis (ST) at 1, 6, and 12 months with an extended follow-up of 2 years. Recommended antiplatelet regimen included clopidogrel and aspirin for 12 months.nnnRESULTSnThe mean age was 57.6xa0±xa010.9 years, 81.8% were males, comorbidity index was 1.20xa0±xa01.33, 68% presented with acute coronary syndrome, 49% had hypertension and 40.8% had diabetes mellitus. One-year clinical follow-up was completed in 987 patients at the time of interim analysis. The incidence of MACE is 0.45 for 1544 person-year follow-up. There were only 03 cases of ST (01 late ST) reported during this time.nnnCONCLUSIONnThis registry demonstrates excellent one-year clinical safety and efficacy of BioMatrix stents. The 1-year result shows that BioMatrix stent may be a suitable alternative as compared to contemporary DESs which are currently available in the market for simple as well complex disease.

Are cardiovascular risk parameters and glycemic levels associated with periodontitis in type 2 diabetes patients? A clinical study

This study investigated the associations between cardiovascular risk parameters, glycemic level and periodontitis in the diabetic adult population. BMI (body mass index), total cholesterol and triglyceride was used as cardiovascular risk measure and glycosylated hemoglobin (HbA1c) was recorded for glycemic levels. Study results provide evidence of significant association between periodontal disease, cardiovascular risk and glycemic levels.

Clinical safety profile of ticagrelor compared to clopidogrel in 1208 patients: Real world evidence

IntroductionnDual antiplatelet treatment is recommended by current clinical practice guidelines for patients undergoing PCI. The PLATO trial showed superiority of ticagrelor to clopidogrel in reducing the rate of death from vascular causes, myocardial infarction and stroke without increase in the rate of overall major bleeding in ACS patients. However, real world evidence in Indian patients is limited. The objective of this study is to compare safety profile of ticagrelor with clopidogrel in real world settings.nnnMethodologynIn this single centered retrospective observational study, a total of 1208 serial patient records undergoing PCI (ACS and stable angina patients as well) treated with Ticagrelor or Clopidogrel were collected and analyzed to look into in hospital outcomes. We excluded the patients data that were incomplete.nnnResultsnIn total of 1208 patients, 604 patients received ticagrelor and similarly 604 patient received clopidogrel. No significant differences in the rates of major life threatening bleeding and any major bleeding were observed between ticagrelor and clopidogrel group (0.2% (nu202f=u202f1) vs. 0.7% (nu202f=u202f4), pu202f=u202f0.18 and 2.8% (nu202f=u202f17) vs. 3% (nu202f=u202f18), pu202f=u202f0.86 respectively). There was increase in minor bleeding rate with ticagrelor compared to clopidogrel (21.4% & 13.6%, pu202f=u202f0.00).nnnConclusionnIn the real world settings, patients undergoing PCI treated with ticagrelor showed similar safety profile compared to clopidogrel but with increase in minor bleeding rate. The observed results were in alignment with PLATO clinical trial.

A case of multivessel PTCA in achondroplasia patient

Dwarfism may be due to several musculoskeletal and hormonal growth disorders. The most common cause is considered to be achondroplasia, a condition due to a mutation affecting the fibroblast growth factor receptor (FGFR) gene 3. Achondroplasia occurs with equal frequency in males and females. It is inherited in an autosomal dominant manner. At least 80% of cases result from a random new mutation. In sporadic cases, a paternal age older than 36 years is common. Despite an estimated prevalence is 1:25,000 in the general population, 3 there is little literature concerning the diagnostic and treatment challenges faced by doctors dealing with CAD in such patients requiring myocardial revascularization.

TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

MeRes100 (Meril Life Science, Gujarat, India) is a novel Sirolimus-eluting BioResorbable Vascular Scaffold System (BRS). This sub study of MeRes-1 trial evaluated the systemic release of sirolimus from the MeRes100 BRS applied for the treatment of de novo native coronary artery lesions.nnThe MeRes-1

New Record of Chagunius chagunio (Cypriniformes: Cyprinidae) from Kangsabati reservoir, West Bengal, India

Chagunius chagunio was first described by Hamilton (1822) as Cyprinus chagunio from the river Yamuna and the northern rivers of Bihar and Bengal. Hora (1928) also described it under the same genus Cyprinus (Linnaeus, 1758). Later, Day (1878) placed the species under the genus Barbus (Cuvier). Subsequently, Smith (1945) placed it under the genus Chagunius (Smith, 1938). Day (1878), in his survey on the Ichthyo-fauna of India, observed that the distribution of C. chagunio (Hamilton) was restricted to Orissa, Bengal, Assam, Bihar and north western provinces to the Punjab, but not reported from Sindh, the Deccan, Western coast, Mysore, Madras and Burma. Shaw and Shebbeare (1937), was in agreement with Day (1878) the regarding distribution of the species. Tilak and Sarma (1982) reported the species from the rivers of North and East India, Pakistan and Thailand. A subsequent survey by Sen (1985) revealed that the fish has a wide distribution in India, in Assam, all along the Himalayas, and in Burma and Thailand. Talwar and Jhingran (1991) reported the species from the Brahmaputra and Ganga drainages all along the Himalayan foot-hills. Recently, Jayaram (1999) reported that the fish is widely distributed in North India along the base of Himalaya, South central Asia, Bangladesh, Myanmar, Nepal, Pakistan and Thailand. As International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 2 (2017) pp. 111-116 Journal homepage: http://www.ijcmas.com